Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada

Contributed by: PR Newswire

Tags

ExCellThera-Health

More Like This

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells

PR Newswire associated0

Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

PR Newswire associated0

Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

PR Newswire associated0

Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy

PR Newswire associated0

THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR)

PR Newswire associated0

A Decade of Cell & Gene Therapy Manufacturing and Major GMP Facility Expansion: Cellex's Track Record of Scalable Excellence